Загрузка...
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line treatment. Although much is known about the pleiotrop...
Сохранить в:
| Опубликовано в: : | Cells |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7072398/ https://ncbi.nlm.nih.gov/pubmed/32041300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9020378 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|